| abstract |
The present application discloses a fusion protein for use as an immunogen enhancer for enhancing antigen-specific T cell responses. The fusion protein comprises: (a) an antigen presenting cell (APC) binding domain or a CD91 receptor binding domain; (b) a protein transduction domain; and (c) an antigen from a pathogen, wherein the APC binding domain or CD91 receptor is The body binding domain is located at the N-terminus of the fusion protein, and the antigen of the pathogen is located at the C-terminus of the protein transduction domain. The protein transduction domain is selected from: (i) a fusion polypeptide comprising a T cell sensitizing signaling peptide, a linker, and a translocation peptide; (it) a T cell sensitizing signaling peptide; and (iii) a length is a transposition peptide of 34-112 amino acid residues. |